Additional immunosuppressants should be strongly considered and promptly given when immune-related adverse events (irAEs) associated with cancer immunotherapy aren’t quickly controlled with corticosteroids, Australian researchers say. Based on a case series of patients treated in Adelaide hospitals, they argue that there is no “compelling evidence” to indicate that immunosuppression will impair benefit from immunotherapy in ...
Melanoma patients need aggressive immunosuppressive therapy for irAEs
By Sunalie Silva
5 Jul 2019